Biol Blood Marrow Transplant: Heterogenetic stem cell transplantation provides long-lasting relief for patients with primary B-cell lymphoma.

The standard treatment for recurring or recurring (rel/ref) primary vertical large B-cell lymphoma (PMBCL) is resuscative therapy followed by auto hematopoietic stem cell transplantation (HSCT).
, however, many patients' diseases are incurable and cannot be carried out with in vitro HSCT, and a significant number of patients will relapse after self-HSCT.
to diffuse large B-cell lymphoma, these patients may be treated with allo (allo) HSCT for curing purposes, but at great risk of morbidity and mortality.
given the emergence of effective immunotherapy for reel/ref PMBCL, it is important to better understand the toxicity and efficacy of allogeneic HSCT in these patients, and these new methods can be used as a new option.
, we reviewed the results of allloHSCT in a multi-center queue of 28 reel/ref PMBCL patients who received transplants at four centers.
most patients (79%) were sensitive to pre-transplant treatment, while 86% received reduced intensity regulation.
total progressive lifetime (PFS), total lifetime (OS), non-relapse death and recurrence cumulative rate in the queue after 5 years was 34%, 45%, 32% and 33%, respectively.
results were significantly better in patients with pre-transplant reactive diseases (50% and 58% in 2 years PFS and OS, respectively) than in patients with refractive diseases (2 years PFS and OS were 0%).
summary, in our multi-center retrospective study, alloHSCT produced lasting relief in some patients treating sensitive diseases before transplantation (44 percent for 5 years PFS) and should be considered in the treatment of patients with reel/ref PMBCL.
.